Centre for Cancer Biomarkers & Biotherapeutics

The Centre for Biomarkers and Biotherapeutics is located in the Barts Cancer Institute, a CRUK Centre of Excellence dedicated to delivering world-leading research. We comprise a multidisciplinary team of surgeons, clinicians, pathologists, basic scientists, biobanking professionals and bioinformaticians; working together towards a common goal.

Our overarching vision is to apply our skills and expertise in developing innovative personalised diagnostic, prognostic and therapeutic strategies. Research focuses on the discovery of new biomarkers for earlier diagnosis, monitoring disease progression and response to treatment, and identifying those individuals at risk of disease, and developing targeted treatments.

Our activities are enhanced by our involvement with local and national biobanks: within the Centre, we have biobanking professionals for specimen management and bioinformaticians for analysing molecular data. Our diversity of research specialities offers an unparalleled opportunity to create a biobanking system in which clinical, molecular and pathologic data are linked.

We are committed to enhancing the teaching experience both for students and the general public through our teaching and outreach activities.

Contact us

Centre Lead: Professor Nick Lemoine

Deputy Centre Lead: Professor Claude Chelala

John Vane Science Centre,
Charterhouse Square,
London EC1M 6BQ

Recent Publications

  • Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol (2019). PMID: 31465093
  • Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. J. Urol. (2019). PMID: 31389764
  • Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Sci Rep. (2019). 9(1):12840. PMID: 31492884
  • AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. Oncotarget. (2019). 10(42):4276-4289. PMID: 31303962

Latest News

  • Congratulations to Professor Nick Lemoine who has been named in the Evening Standard's Progress 1000 list, which recognises London's most influential people.
  • Join Professor Chelala and her team at the NIHR Great Ormond Street Hospital Biomedical Research Centre Family Fun Day on Saturday 26th of October. This is a free event with a range of scientific activities suitable for ages 5+.
  • Congratulations to Professor Yong-Jie Lu who found a new blood test able to detect the presence of aggressive prostate cancer with great accuracy.
  • Professor Crnogorac-Jurcevic is leading the UroPanc clinical study that will validate the use of a urine test that can detect early stage pancreatic cancer.

Areas of focus

Solid Tumour Research
Molecular Imaging
Translational Bioinformatics
Oncolytic Immunotherapy
Clinical Translation

Schmid | Powles | Berney | Szlosarek